Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047734 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,320
- Enrollment target
NCT02047734: Completed Phase 3 study, sponsored by Celgene.
NCT02047734 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,320 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02047734, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
Primary Outcome
A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for \> 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS asses
Interventions
- DRUG Ozanimod
- DRUG Interferon beta-1a
- DRUG Ozanimod placebo
- DRUG Interferon beta-1a placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2017-04-13 |
| Phase | Phase 3 |
What the finished NCT02047734 record still lists
NCT02047734 is an interventional study that assigns participants to a tested intervention. Its 1,320 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% higher).
The record links to 0 conditions, and to 4 interventions - of which Ozanimod is the first listed.
NCT02047734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02047734 about?
NCT02047734 is a clinical study titled "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis". This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical rel...
What is the current status of trial NCT02047734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,320 participants. The study started on 2013-12-03. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT02047734?
The interventions under investigation include: Ozanimod (DRUG), Interferon beta-1a (DRUG), Ozanimod placebo (DRUG), Interferon beta-1a placebo (DRUG).
Who is sponsoring clinical trial NCT02047734?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02047734's enrollment target sits among peer trials
1,320 185th of 2000 higher than 1,816 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06557005 · 1,320 participants · NA
Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions
- NCT07213908 · 1,320 participants · NA
Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
- NCT05097287 · 1,324 participants · Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI